- Home
- IFRX vs CCIF Comparison
IFRX vs CCIF Comparison
Compare IFRX & CCIF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IFRX
- CCIF
- Stock Information
- Founded
- IFRX 2007
- CCIF 2011
- Country
- IFRX Germany
- CCIF United States
- Employees
- IFRX N/A
- CCIF N/A
- Industry
- IFRX Biotechnology: Pharmaceutical Preparations
- CCIF Finance/Investors Services
- Sector
- IFRX Health Care
- CCIF Finance
- Exchange
- IFRX Nasdaq
- CCIF Nasdaq
- Market Cap
- IFRX 117.8M
- CCIF 130.8M
- IPO Year
- IFRX 2017
- CCIF N/A
- Fundamental
- Price
- IFRX $1.15
- CCIF $6.93
- Analyst Decision
- IFRX Strong Buy
- CCIF
- Analyst Count
- IFRX 2
- CCIF 0
- Target Price
- IFRX $9.00
- CCIF N/A
- AVG Volume (30 Days)
- IFRX 337.7K
- CCIF 76.9K
- Earning Date
- IFRX 05-07-2025
- CCIF 01-01-0001
- Dividend Yield
- IFRX N/A
- CCIF 25.90%
- EPS Growth
- IFRX N/A
- CCIF N/A
- EPS
- IFRX N/A
- CCIF N/A
- Revenue
- IFRX $171,642.00
- CCIF N/A
- Revenue This Year
- IFRX $106.72
- CCIF N/A
- Revenue Next Year
- IFRX $66.89
- CCIF N/A
- P/E Ratio
- IFRX N/A
- CCIF N/A
- Revenue Growth
- IFRX 162.79
- CCIF N/A
- 52 Week Low
- IFRX $1.01
- CCIF $7.43
- 52 Week High
- IFRX $2.82
- CCIF $10.16
- Technical
- Relative Strength Index (RSI)
- IFRX 38.70
- CCIF 29.04
- Support Level
- IFRX $1.01
- CCIF $6.56
- Resistance Level
- IFRX $1.30
- CCIF $7.90
- Average True Range (ATR)
- IFRX 0.13
- CCIF 0.19
- MACD
- IFRX 0.02
- CCIF -0.06
- Stochastic Oscillator
- IFRX 34.15
- CCIF 27.61
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
About CCIF Carlyle Credit Income Fund Shares of Beneficial Interest
Carlyle Credit Income Fund is a non-diversified, closed-end management investment company. The Fund's primary investment objective is to generate current income, with a secondary objective to generate capital appreciation. The Fund seeks to achieve its investment objective by investing predominantly in equity and junior debt tranches of collateralized loan obligations, that are collateralized by a portfolio consisting mainly of below-investment-grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.